000274230 001__ 274230
000274230 005__ 20240229154929.0
000274230 0247_ $$2doi$$a10.1002/smtd.202201605
000274230 0247_ $$2pmid$$apmid:36908010
000274230 0247_ $$2altmetric$$aaltmetric:144442985
000274230 037__ $$aDKFZ-2023-00516
000274230 041__ $$aEnglish
000274230 082__ $$a620
000274230 1001_ $$0P:(DE-He78)5f4f1502f9cd9f89b1f6d14d76c68bee$$aMircetic, Jovan$$b0$$udkfz
000274230 245__ $$aCRISPR/Cas9 Screen in Gastric Cancer Patient-Derived Organoids Reveals KDM1A-NDRG1 Axis as a Targetable Vulnerability.
000274230 260__ $$aWeinheim$$bWILEY-VCH Verlag GmbH & Co. KGaA$$c2023
000274230 3367_ $$2DRIVER$$aarticle
000274230 3367_ $$2DataCite$$aOutput Types/Journal article
000274230 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1687854661_19593
000274230 3367_ $$2BibTeX$$aARTICLE
000274230 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274230 3367_ $$00$$2EndNote$$aJournal Article
000274230 500__ $$a2023 Jun;7(6):e2201605
000274230 520__ $$aViability CRISPR screens have proven indispensable in parsing genome function. However, their application in new, more physiologically relevant culturing systems like patient-derived organoids (PDOs) has been much slower. To probe epigenetic contribution to gastric cancer (GC), the third leading cause of cancer-related deaths worldwide, the first negative selection CRISPR screen in GC PDOs that faithfully preserve primary tumor characteristics is performed. Extensive quality control measurements showing feasibility of CRISPR screens in primary organoid culture are provided. The screen reveals the histone lysine demethylase-1A (KDM1A) to constitute a GC vulnerability. Both genetic and pharmacological inhibition of KDM1A cause organoid growth retardation. Further, it is shown that most of KDM1A cancer-supporting functions center on repression of N-myc downstream regulates gene-1 (NDRG1). De-repression of NDRG1 by KDM1A inhibitors (KDM1Ai) causes inhibition of Wnt signaling and a strong G1 cell cycle arrest. Finally, by profiling 20 GC PDOs, it is shown that NDRG1 upregulation predicts KDM1Ai response with 100% sensitivity and 82% specificity in the tested cohort. Thus, this work pioneers the use of negative selection CRISPR screens in patient-derived organoids, identifies a marker of KDM1Ai response, and accordingly a cohort of patients who may benefit from such therapy.
000274230 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000274230 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000274230 650_7 $$2Other$$aCRISPR screen
000274230 650_7 $$2Other$$aKDM1A-NDRG1 axis
000274230 650_7 $$2Other$$aepigenetic regulators
000274230 650_7 $$2Other$$agastric cancer
000274230 650_7 $$2Other$$apatient-derived organoids
000274230 7001_ $$0P:(DE-He78)dd60ad1c45db7fcacc5be5238ad17e7d$$aCamgöz, Aylin$$b1$$udkfz
000274230 7001_ $$0P:(DE-HGF)0$$aAbohawya, Moustafa$$b2
000274230 7001_ $$aDing, Li$$b3
000274230 7001_ $$aDietzel, Julia$$b4
000274230 7001_ $$aTobar, Sebastián García$$b5
000274230 7001_ $$aPaszkowski-Rogacz, Maciej$$b6
000274230 7001_ $$aSeidlitz, Therese$$b7
000274230 7001_ $$aSchmäche, Tim$$b8
000274230 7001_ $$aMehnert, Marie-Christin$$b9
000274230 7001_ $$aSidorova, Olga$$b10
000274230 7001_ $$aWeitz, Jürgen$$b11
000274230 7001_ $$00000-0002-4577-3344$$aBuchholz, Frank$$b12
000274230 7001_ $$0P:(DE-HGF)0$$aStange, Daniel E$$b13
000274230 773__ $$0PERI:(DE-600)2884448-8$$a10.1002/smtd.202201605$$gp. 2201605 -$$n6$$pe2201605$$tSmall Methods$$v7$$x2366-9608$$y2023
000274230 909CO $$ooai:inrepo02.dkfz.de:274230$$pVDB
000274230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5f4f1502f9cd9f89b1f6d14d76c68bee$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000274230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)dd60ad1c45db7fcacc5be5238ad17e7d$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000274230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000274230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000274230 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000274230 9141_ $$y2023
000274230 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2022-11-12$$wger
000274230 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-12
000274230 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-12
000274230 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSMALL METHODS : 2022$$d2023-08-22
000274230 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-22
000274230 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-22
000274230 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-22
000274230 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-22
000274230 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-22
000274230 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-22
000274230 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-22
000274230 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bSMALL METHODS : 2022$$d2023-08-22
000274230 9201_ $$0I:(DE-He78)DD01-20160331$$kDD01$$lDKTK Koordinierungsstelle Dresden$$x0
000274230 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000274230 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000274230 980__ $$ajournal
000274230 980__ $$aVDB
000274230 980__ $$aI:(DE-He78)DD01-20160331
000274230 980__ $$aI:(DE-He78)B062-20160331
000274230 980__ $$aI:(DE-He78)HD01-20160331
000274230 980__ $$aUNRESTRICTED